Daphne L. Farrington
Publications by Year
Research Areas
Melanoma and MAPK Pathways, Colorectal Cancer Treatments and Studies, PI3K/AKT/mTOR signaling in cancer, Cancer-related Molecular Pathways, Wnt/β-catenin signaling in development and cancer
Most-Cited Works
- → An Affinity Capture Elution (ACE) assay for detection of anti-drug antibody to monoclonal antibody therapeutics in the presence of high levels of drug(2007)152 cited
- → A First-in-Human Phase I Study of the Oral p38 MAPK Inhibitor, Ralimetinib (LY2228820 Dimesylate), in Patients with Advanced Cancer(2015)137 cited
- → A first-in-human phase I dose-escalation, pharmacokinetic, and pharmacodynamic evaluation of intravenous LY2090314, a glycogen synthase kinase 3 inhibitor, administered in combination with pemetrexed and carboplatin(2015)70 cited
- → A randomized, double-blind, placebo-controlled phase 1b/2 study of ralimetinib, a p38 MAPK inhibitor, plus gemcitabine and carboplatin versus gemcitabine and carboplatin for women with recurrent platinum-sensitive ovarian cancer(2019)66 cited
- → TGF-β signalling-related markers in cancer patients with bone metastasis(2008)66 cited
- → Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer(2017)48 cited
- Delayed apoptotic responses associated with radiation-induced neoplastic transformation of human hybrid cells.(1999)
- → Loss of Suppressor Loci on Chromosomes 11 and 14 May Be Required for Radiation-Induced Neoplastic Transformation of HeLa × Skin Fibroblast Human Cell Hybrids(1998)30 cited
- → A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer(2019)30 cited
- → A phase 1 study of LY3076226, a fibroblast growth factor receptor 3 (FGFR3) antibody–drug conjugate, in patients with advanced or metastatic cancer(2021)26 cited